CNTX Earnings — Context Therapeutics Inc. Common Stock Post-ER Performance | BigEarnings
CNTX — Context Therapeutics Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$2.85
Market Cap$261.9M
P/E—
52W Range$0.52 – $3.62
Next Earnings2026-08-05
About Context Therapeutics Inc. Common Stock
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
